• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,569.39 827.57
( 1.08%)
Global Indices
Nasdaq
52,658.24 149.83
(0.29%)
Dow Jones
7,594.79 30.15
(0.40%)
Hang Seng
68,634.11 890.26
(1.31%)
Nikkei 225
10,498.02 25.57
(0.24%)
Forex
USD-INR
95.45 -0.01
(-0.01%)
EUR-INR
109.10 0.17
(0.15%)
GBP-INR
127.94 0.35
(0.28%)
JPY-INR
0.59 0.00
(0.03%)

EQUITY - MARKET SCREENER

Shree Ganesh Remedies Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
540737
INE414Y01015
126.9843008
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
49.92
886.89
EPS(TTM)
Face Value()
Div & Yield %
13.84
10
0
 

Embassy Development surges on strong Q1 pre-sales
Jul 08,2026
Collections stood at Rs 496 crore in Q1 FY27, up 54% against Rs 322 crore collected in Q1 FY26.

As of 30 June 2026, the company’s net institutional debt stood at around Rs 3,363 crore, after adjusting for cash and cash equivalents of approximately Rs 1,202 crore.

Separately, the company's board approved raising additional funds of up to Rs 1,170 crore through the issuance of non-convertible debentures (NCDs) on a private placement basis in one or more tranches and/or series. With this approval, the overall issue size has been enhanced from up to Rs 400 crore to up to Rs 1,570 crore. The face value of each NCD is Rs 1 lakh.

Embassy Developments is a real estate developer of residential, commercial, and SEZ projects. The company reported a consolidated net loss of Rs 323.78 crore in Q4 FY26 as against a net profit of Rs 129.53 crore in Q4 FY25. Revenue from operations declined 61.5% year on year to Rs 342.46 crore in Q4 FY26.